This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Meyerhardt is ...
Six months of chemotherapy in low-risk stage 3 colorectal cancer patients increases neuropathy compared to three months. IDEA collaboration found similar survival outcomes between three and six months ...
Polymorphism in sodium-channel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin This is an ASCO ...
The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback